English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2019 → 2020: 47.47%
Price change 2020 → 2021: -55.14%
Price change 2021 → 2022: -2.14%
Price change 2022 → 2023: 38.85%
Price change 2023 → 2024: 171.69%
Price change 2024 → 2025: 34.28%
Price change 2025 → 2026: -9.76%
Price change 2026 (year to date): -12.30%
Financial growth
Revenue CAGR (7 years): 74.71%
Earnings CAGR (7 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 2.07
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -45.31
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 23.46% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="HIMS" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Hims & Hers Health, Inc. | – | 2.07 | +74.7 % | 🔒 |
| Oscar Health, Inc. | 21.7 | 0.44 | +66.3 % | – |
| Bio-Rad Laboratories, Inc. | 40.1 | 0.20 | +2.0 % | – |
| bioMérieux S.A. | 22.8 | 0.11 | +7.6 % | ★ 4/5 |
| Virbac S.A. | 19.3 | 0.26 | +6.5 % | ★ 4/5 |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Hims & Hers Health, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 149 m | -18.1 m | -12.2 % | n/a |
| 2021 | 272 m | -108 m | -39.6 % | +82.8 % |
| 2022 | 527 m | -65.7 m | -12.5 % | +93.8 % |
| 2023 | 872 m | -23.5 m | -2.7 % | +65.5 % |
| 2024 | 1.5 bn | 126 m | 8.5 % | +69.3 % |
| 2025 | 2.3 bn | 128 m | 5.5 % | +59.0 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Hims & Hers Health, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 247 m | 180 m | 221 m | 300 m | 577 m |
| Total Debt | 5.5 m | 5.3 m | 9.9 m | 11.3 m | 1.1 bn |
| Net Debt | -66.3 m | -41.5 m | -86.7 m | -209 m | 892 m |
| Equity | 335 m | 312 m | 344 m | 477 m | 541 m |
| Total assets | 421 m | 366 m | 441 m | 708 m | 2.2 bn |
| Operating cash flow | -34.4 m | -26.5 m | 73.5 m | 251 m | 300 m |
| Investments (capex) | 832,000 | 2.7 m | 17.2 m | 41.7 m | 226 m |
| Free cash-flow | -39.4 m | -33.8 m | 47.0 m | 198 m | 74.0 m |
| Share buybacks | 22.0 m | 0 | 2.0 m | 83.0 m | 90.0 m |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Hims & Hers Health, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Hims & Hers Health, Inc. | 6.2 bn | n/a | 5.5 % |
| LifeMD, Inc. LFMD | 111 m | n/a | -3.7 % |
| Perrigo Company plc PRGO | 2.2 bn | 6.3 | -33.5 % |
| The Honest Company, Inc. HNST | 447 m | 65.4 | -4.2 % |
| e.l.f. Beauty, Inc. ELF | 6.6 bn | 28.0 | 8.5 % |
| Helen of Troy Limited HELE | 676 m | 8.8 | 6.5 % |
| The Estée Lauder Companies Inc. EL | 39.6 bn | 49.4 | -7.9 % |
| Coty Inc. COTY | 3.0 bn | 18.9 | -6.2 % |
| Edgewell Personal Care Company EPC | 1.3 bn | 15.5 | 1.1 % |
| Sector median (NYSE) | 26.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Hims & Hers Health, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Average target over the last 3 months: 32.60 USD (5 targets).
Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Hims & Hers Health, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 09/11/2026. Expected EPS: 0.06.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Hims & Hers Health, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| BlackRock | 28.7 m | 995 m | 0.0 % | +9.0 % | 2026Q2 |
| Vanguard Group | 20.9 m | 679 m | 0.0 % | +7.2 % | 2025Q4 |
| State Street | 16.3 m | 565 m | 0.0 % | +118.4 % | 2026Q2 |
| Morgan Stanley | 7.2 m | 248 m | 0.0 % | -19.5 % | 2026Q2 |
| Geode Capital Management | 5.7 m | 197 m | 0.0 % | +9.3 % | 2026Q2 |
| Goldman Sachs | 5.2 m | 179 m | 0.0 % | +110.8 % | 2026Q2 |
| JPMorgan Chase | 4.8 m | 159 m | 0.0 % | -9.0 % | 2026Q2 |
| Fidelity | 4.3 m | 150 m | 0.0 % | +4,535.2 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 28/10/2026 | Boughton Soleil | sale | 95,551 USD |
| 14/10/2026 | Boughton Soleil | sale | 100,577 USD |
| 01/10/2026 | Okupe Oluyemi | sale | 59,400 USD |
| 30/09/2026 | Boughton Soleil | sale | 100,957 USD |
| 22/09/2026 | Okupe Oluyemi | sale | 876,846 USD |
| 17/09/2026 | Okupe Oluyemi | sale | 354,861 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Hims & Hers Health, Inc.
What is the Hims & Hers Health, Inc. share price?
Latest recorded price: 26.00 USD on 06/11/2026, for a market cap of 5.8 bn USD.
What is the revenue of Hims & Hers Health, Inc.?
2.3 bn USD for fiscal year 2025, with net income of 128 m USD (net margin 5.5 %).
When does Hims & Hers Health, Inc. report its next earnings?
The next release is expected on 09/11/2026. EPS expected by analysts: 0.06.
What do analysts say about Hims & Hers Health, Inc.?
Out of 20 analysts: 7 buy or strong buy, 13 hold, 0 sell or strong sell. Average price target: 32.60 USD, i.e. +17.8 % from the share price.
Is Hims & Hers Health, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US4330001060).
How many employees does Hims & Hers Health, Inc. have?
1,637 full-time employees according to the latest published profile.
Who runs Hims & Hers Health, Inc.?
Andrew Dudum is the company's chief executive.
Which large funds own Hims & Hers Health, Inc.?
As of 2026Q2, among the large funds tracked: BlackRock, Vanguard Group, State Street, Morgan Stanley, Geode Capital Management.